A decorative graphic in the top left corner consisting of a blue 'J' shape and a green and yellow swoosh element.

January 22, 2016

**Bombay Stock Exchange Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip code: 512529

Dear Sir/ Madam,

**Sub: Press release of the Company titled “Sequent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare”**

We are pleased to enclose hereby a press release of the Company titled “**Sequent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare**” along with Disclosure as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.


This is for your kind information.

Thanking you,

Yours faithfully,  
**For Sequent Scientific Limited**

A handwritten signature in blue ink, appearing to read "Kannan P R".

**Kannan P R**  
**Chief Financial Officer**



**SeQuent Scientific Limited**

**Corporate Office :** Star I, Opp. IIM, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India. Tel: +91 80 6784 0340 Fax: +91 80 6784 0400

**Regd. Office :** 301, 3rd Floor, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W), Mumbai - 400 604, India. Tel: +91 22 4111 4777 Fax +91 22 4111 4754

CIN : L99999MH1985PLC036685 | Email : info@sequent.in | www.sequent.in

## SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare

**Mumbai, January 22, 2016:** SeQuent Scientific Limited today announced that it is acquiring a controlling stake in Indo Phyto Chemicals Pvt Ltd (IPC), a New Delhi based pharmaceutical Company, focused on Female Healthcare. The transaction is subject to customary closing conditions.

IPC is a fully integrated company with a portfolio of steroids and hormonal APIs and having its manufacturing base in Uttarakhand. The company has capabilities in both fermentation and chemical synthesis, giving it a unique ability to produce APIs from the basic starting materials that are extracted from plants. IPC currently produces 14 APIs and has an aggressive R&D pipeline including 20 more under development. The company has already commenced filings in the regulated markets.

Under the terms of the agreement, SeQuent is acquiring 51% of IPC and the remaining 49% will continue to be held by the Promoters of IPC, who will also join the Sequent management team in driving the business.

Commenting on the development, **Mr. Manish Gupta, Managing Director of SeQuent Scientific** said that *"We are pleased to announce the acquisition of a majority stake in IPC, which gives us an entry into the niche female healthcare segment, with specific focus on steroids and hormones. This is in line with our business strategy of focusing on niche and complex segments in the market place. With IPC's enhanced product portfolio and our strong global foot print, we believe the business will enter the next orbit of growth."*

### About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-SEQUENT/512529) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), niche Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

SeQuent 's Animal Health business is operated through its subsidiary Alivira Animal Health Ltd and SeQuent is poised to emerge as a global powerhouse in animal health business, built on a platform of superior quality and compliance.

### For Queries, please contact

#### Kannan P R

Chief Financial Officer  
Tel: +91 80 67840327  
[Kannan.pr@sequent.in](mailto:Kannan.pr@sequent.in)

#### Ankit Gupta

Christensen Investor Relations  
Tel: +91 22 42150210  
[ankitgupta@christensenir.com](mailto:ankitgupta@christensenir.com)

#### SeQuent Registered Office

SeQuent Scientific Limited  
301/A, 'Dosti Pinnacle',  
Plot No. E7, Road No. 22,  
Wagle Industrial Area, Thane (W), Maharashtra,  
India  
CIN: L99999MH1985PLC036685  
BSE Code: 512529  
ISIN: INE807F01019  
REUTERS: SEQU.BO  
Website: [www.sequent.in](http://www.sequent.in)

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

FOR SEQUENT SCIENTIFIC LTD.

Authorized Signatory

**Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sr. No	Particulars	Description	
1.	Name of the Target entity, details in brief such as size, turnover etc.	Indo Phyto Chemicals Private Limited ("IPC"). IPC is a vertically integrated steroid and hormone manufacturer specializing in high actives and complex chemistry	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/promoter group/group companies have any interest in the entity being acquired	No	
3.	Industry to which Target entity being acquired belongs	Manufacturing and Development of Pharmaceutical products	
4.	Objects and effects of acquisition	Entry into steroids and hormone segment, a niche area requiring dedicated manufacturing and with limited competition	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None	
6.	Indicative time period for completion	Expected to be completed by March 31, 2016	
7.	Nature of consideration	Cash	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	51.02% of Total Voting Capital	
9.	Cost of acquisition or the price at which the shares are acquired	Rs. 68.5 Mn	
10.	Brief background about entity acquired in terms of:		
a.	Products/line of business acquired	Vertically integrated steroid and hormone manufacturer	
b.	Date of incorporation	23/02/1978	
c.	History of last 3 years turnover	Financial year	Turnover (in Rs. Mn)
		2014-15	675
		2013-14	358
		2012-13	266
d.	Country in which the acquired entity has presence	India	
e.	Any other significant information	Nil	

For SEQUENT SCIENTIFIC LTD.

  
Authorized Signatory